Latest News

Circassia Acquires North American and Japanese rights to Dopexamine

08 October 2008

Circassia Initiates Further Phase II Clinical Study Of ToleroMune® Anti-Allergy Technology

02 October 2008

Circassia Achieves Successful Phase II Clinical Results With ToleroMune® Anti-Allergy Technology

10 September 2008

Circassia Announces the Appointment of Guy Layton as Director of Alloimmune Projects

02 June 2008

Circassia Announces the Appointment of Pascal Hickey as Vice President, Critical Care

21 April 2008

Previous news articles

Did you know?

The average bed could be home to up to 1.5 million house dust mites